MONMOUTH JUNCTION, N.J., Oct. 17, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc., (OTCBB:VQPH), will be presenting at the BIO InvestorForum 2005 Conference at 11:20 AM PST Thursday, October 20th at the Palace Hotel in San Francisco. VioQuest is one of 190 public and venture stage biotechnology companies scheduled to present at the conference, which is organized by the Biotechnology Industry Organization (BIO).
Daniel Greenleaf, President and CEO of VioQuest, will provide a Company overview and an update on the development of the Company's strategy to in-license targeted oncology therapeutics, including Sodium Stibogluconate (SSG), which recently began a Phase I clinical trial at the Cleveland Clinic Cancer Center.
BIO InvestorForum 2005 is a national investor forum that will be attended by institutional investors, venture and private equity investors, as well as research analysts and bankers representing leading banks in the biotechnology sector. The goal of the conference is to explore investment trends and opportunities in life sciences, with a focus on public and venture-stage growth companies.
About VioQuest Pharmaceuticals, Inc.
VioQuest Pharmaceuticals, Inc.'s strategy is to acquire and develop late preclinical and early clinical-stage therapies for oncological, viral and autoimmune diseases. The Company recently entered into a definitive merger agreement to acquire Greenwich Therapeutics, which owns exclusive license rights to two anti-cancer agents -- sodium stibogluconate (SSG) and triciribine (TCN-P). VioQuest's life science subsidiary, Chiral Quest, Inc., a pioneer in asymmetric synthesis, offers proprietary chiral catalysts and synthesis expertise for creating important chiral intermediates and products, which improve the safety and efficacy of pharmaceutical products. Through Chiral Quest, VioQuest provides products and services to fine chemical manufacturers and twelve of the top eighteen pharmaceutical companies worldwide. For more information please visit www.vioquestpharm.com.
Forward-Looking Statements: This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of VioQuest's research programs and compounds will be successfully commercialized. Risks, uncertainties and assumptions also include the possibility that the market for the sale of certain products may not develop as expected; and that development of these products may not proceed as planned. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2004. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.